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S U M M A R Y
Background: Antigenic drift and shift of inﬂuenza viruses require frequent reformulation of inﬂuenza
vaccines. In addition, seasonal inﬂuenza vaccines are often mismatched to the epidemic inﬂuenza
strains. This stresses the need for a universal inﬂuenza vaccine.
Methods: BALB/c mice were vaccinated with the trivalent live attenuated (LAIV; FluMist) or inactivated
(TIV; FluZone) inﬂuenza vaccines and challenged with PR8 (H1N1), FM/47 (H1N1), or HK/68 (H3N2)
inﬂuenza virus. Cytokines and antibody responses were tested by ELISA. Furthermore, different LAIV
dosages were applied in BALB/c mice. LAIV vaccinated mice were also depleted of T-cells and challenged
with PR8 virus.
Results: LAIV induced signiﬁcant protection against challenge with the non-vaccine strain PR8 inﬂuenza
virus. Furthermore, protective immunity against PR8 was dose-dependent. Of note, interleukin 2 and
interferon gamma cytokine secretion in the lung alveolar ﬂuid were signiﬁcantly elevated in mice
vaccinated with LAIV. Moreover, T-cell depletion of LAIV vaccinated mice compromised protection,
indicating that T-cell-mediated immunity is required. In contrast, passive transfer of sera from mice
vaccinated with LAIV into naı¨ve mice failed to protect against PR8 challenge. Neutralization assays in
vitro conﬁrmed that LAIV did not induce cross-strain neutralizing antibodies against PR8 virus. Finally,
we showed that three doses of LAIV also provided protection against challenge with two additional
heterologous viruses, FM/47 and HK/68.
Conclusions: These results support the potential use of the LAIV as a universal inﬂuenza vaccine under a
prime–boost vaccination regimen.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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Inﬂuenza viruses are single-stranded, negative-sense RNA
viruses with a genome encoding 11–13 viral proteins.1 Inﬂuenza
viruses are divided into subtypes based on hemagglutinin (HA) and
neuraminidase (NA), two main structural surface proteins that
induce speciﬁc antibodies during inﬂuenza virus infection. There
are 17 HA and 10 NA subtypes.2–5 The inﬂuenza viruses circulating
in humans are mainly H1N1, H3N2, and B inﬂuenza viruses. Last
century, there were three inﬂuenza pandemics. The 1918 Spanish
inﬂuenza pandemic was caused by an H1N1 inﬂuenza virus
originating from an avian inﬂuenza virus,6 while the 1957 Asian
inﬂuenza (H2N2) and 1968 Hong Kong inﬂuenza (H3N2) pandemic* Corresponding author. Tel.: +1 915 2154244.
E-mail address: mt.zeng@ttuhsc.edu (M. Zeng).
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1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).viruses were descendants of the 1918 human inﬂuenza virus and
avian inﬂuenza virus, respectively.7 In contrast, a novel H1N1
inﬂuenza virus emerged in 2009 to produce the ﬁrst human
inﬂuenza pandemic of the twenty-ﬁrst century; this reassorted
virus was initially named swine-origin inﬂuenza virus (S-OIV).8
Within 1 year, this new S-OIV had spread to over 214 countries and
caused over 18 000 conﬁrmed deaths worldwide.9
The frequent evolution of inﬂuenza viruses allows them to
escape immunity induced by annual inﬂuenza vaccination. This is
made possible by point mutations occurring around the conserved
receptor binding site of HA protein. Sometimes, reassortment of
HA among different inﬂuenza virus subtypes, or antigenic shift,
results in a new inﬂuenza virus subtype for which the population
lacks protective immunity and can consequently lead to a new
inﬂuenza pandemic. Thus, the inﬂuenza viruses must be under
surveillance and the inﬂuenza vaccine must be reformulated each
year to keep pace with the mutation of inﬂuenza viruses. Theciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
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development of a matching vaccine is a time-consuming process,
and in many countries, vaccines did not become available until
after the peak of the pandemic.10 The rapid dissemination of the
2009 pandemic inﬂuenza viruses and the potential for H5N1 virus
infection in humans also underscore the urgent need for universal
inﬂuenza vaccines that elicit cross-immunity against different
inﬂuenza virus strains.2
Current inﬂuenza vaccines rely on trivalent inactivated or live
attenuated vaccine (TIV and LAIV, respectively). FluMist (LAIV,
nasal spray) and FluZone (TIV, intramuscular injection) are
designed for protection against seasonal inﬂuenza virus infection.
Cross-strain protection in humans as elicited by seasonal inﬂuenza
vaccination is rare.11,12 Furthermore, two studies showed that
prior seasonal inﬂuenza vaccination did not have a signiﬁcant
effect on the incidence of 2009 pandemic inﬂuenza virus
infection.13,14 In contrast, data collected during the 2009 H1N1
inﬂuenza pandemic indicated that a large segment of the
population previously exposed to an inﬂuenza infection needed
only one dose of the novel pandemic H1N1 inﬂuenza vaccine to
sufﬁciently elicit protective humoral immunity,15 suggesting a
priming effect by previous inﬂuenza infection.
Similar priming effects have been observed in mice. Mice that
were infected with seasonal H1N1 inﬂuenza, or vaccinated with
seasonal LAIV (s-LAIV) or pandemic H1N1 LAIV (p-LAIV) prior to p-
LAIV had increased antibody titers as measured by ELISA.16
Furthermore, seasonal H1N1 infection followed by p-LAIV vaccina-
tion, or two doses of p-LAIV, completely protected the mouse
respiratory tract from challenge with pandemic H1N1. However,
while two-dose vaccination with p-LAIV leads to robust neutralizing
antibody titers against pandemic H1N1, infection with seasonal
H1N1 inﬂuenza followed by p-LAIV vaccination lacks a signiﬁcant
neutralizing antibody response, but elicits strong cellular
responses.16 Thus, because cross-reactive neutralizing antibodies
may be lacking, an effective way to decrease the severity of inﬂuenza
A virus infection may be through cross-strain T-cell immunity.
In this study, we evaluated protection against lethal heterolo-
gous inﬂuenza virus challenge in mice vaccinated with LAIV
(FluMist) and TIV (FluZone) using varying prime–boost regimens.
In addition, we evaluated if T-cell immunity induced by LAIV is
crucial for cross-protection against heterologous inﬂuenza infec-
tion. Insight into protective, heterologous immunity will be crucial
in designing and implementing new methods to control future
inﬂuenza epidemics and pandemics.
2. Methods
2.1. Cell culture, vaccines, inﬂuenza viruses, and mice
Madin–Darby canine kidney epithelial cells (MDCK) were
cultivated in modiﬁed Eagle’s medium (MEM) with 10% fetal
calf serum, 1 mM sodium pyruvate, 1 nonessential amino acids,
5 mg/ml gentamicin sulfate, and 4 mM L-glutamine. Seasonal
(2011–2012) inﬂuenza vaccines FluMist (lot number 501096P) and
FluZone (lot number UH467AA) were manufactured by MedIm-
mune (Gaithersburg, MD, USA) and Sanoﬁ Pasteur (Swiftwater, PA,
USA), respectively. PR8 inﬂuenza virus (H1N1) was produced and
rescued using the inﬂuenza viral plasmid system consisting of
pHW-PB2, pHW-PB1, pHW-PA, pHW-HA, pHW-NP, pHW-NA,
pHW-M, pHW-NS and propagated in 10-day-old embryonated
eggs. The LD50 (median lethal dose) of inﬂuenza viruses in mice
were determined using the Reed–Muench method. Inﬂuenza virus
FM/47 (H1N1) was a gift from Dr Richard J. Webby, and HK/68
(H3N2) was provided by the Biodefense and Emerging Infections
Research Resources Repository (BEI Resources). Embryonated eggs
and BALB/c mice were purchased from Charles Rivers Laboratories(Wilmington, MA, USA). BALB/c mice were housed under speciﬁc
pathogen-free conditions in the Laboratory Animal Resources
Center facilities at Texas Tech University Health Sciences Center.
2.2. Vaccination and challenge of mice with PR8 (H1N1) inﬂuenza
virus
Sixty-four 6–8-week-old BALB/c mice were divided into groups
of eight. The following control groups were included: (1) negative
control, administered with 50 ml phosphate-buffered saline (PBS)
intranasally, and (2) positive control, inoculated intranasally with
25 plaque-forming units (PFU) of PR8 inﬂuenza viruses in 50 ml
PBS. In the remaining groups, mice were primed with 10 ml FluMist
in 40 ml PBS (in a total volume of 50 ml) or 55 ml FluZone on day 0,
and boosted with the same dose of FluZone or FluMist on day 28. To
test whether intranasal vaccination with FluZone and intramus-
cular vaccination with FluMist induce a potent humoral immune
response, two groups were set. In one group, mice were primed and
boosted with 10 ml FluMist in 40 ml PBS intramuscularly. In the
other group, mice were primed and boosted with 55 ml FluZone
intranasally. Serum was collected and stored at 80 8C until
further testing. On day 42 post-vaccination, all mice were
challenged with 100  LD50 PR8 virus and observed for clinical
symptoms. When one mouse died, the weight calculation for this
group ceased. At the end of the experiments, animals used in the
experiments were euthanatized in a CO2 chamber in a manner
consistent with the AVMA Guidelines for the Euthanasia of
Animals (2013 edition).17
2.3. Lung alveolar ﬂuid collection
Forty-eight 6–8-week-old BALB/c mice were divided into six
groups. Two negative control groups were administered with 50 ml
PBS intranasally for each mouse, two positive control groups were
vaccinated intranasally with 25 PFU PR8 inﬂuenza viruses in 50 ml
PBS for each mouse, and two groups were vaccinated intranasally
with 10 ml FluMist in 40 ml PBS for each mouse. Boost vaccination
was performed on day 28. On day 34, one group from each of the
negative control, positive control, and FluMist groups was
sacriﬁced to collect lung alveolar ﬂuid for the analysis of cytokines.
On day 42, the remaining mice were sacriﬁced to collect lung
alveolar ﬂuid to test IgA.
2.4. Enzyme-linked immunosorbent assay (ELISA)
Immune sera were tested for inﬂuenza-speciﬁc IgG and
antibodies by quantitative ELISA methods, as described previous-
ly,18,19 using FluZone as the plate-coating antigen. Similar ELISA
methods were used to measure inﬂuenza-speciﬁc IgA antibodies,
interferon gamma (IFN-g), tumor necrosis factor alpha (TNF-a),
interleukin 2 (IL-2), and interleukin 4 (IL-4) cytokine levels in the
lung alveolar ﬂuid. All antibodies used for cytokine ELISA were
purchased from BD Biosciences (San Jose, CA, USA).
2.5. Protection experiment with different dosages of LAIV
Thirty-two 6–8-week-old BALB/c mice were divided into four
groups. One group was set as the negative control and inoculated
intranasally with 50 ml PBS. Mice in the second group were
vaccinated with 10 ml FluMist in 40 ml PBS. Mice in the third group
were vaccinated with FluMist and boosted at day 15 after primary
vaccination, and the fourth group was vaccinated with FluMist and
boosted twice at day 15 and day 30 after primary vaccination,
respectively. At 15 days after second boost, all mice were challenged
with 100  LD50 PR8 inﬂuenza virus. After being challenged, mice
were observed and recorded for clinical symptoms and survival.
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Cross-strain neutralization antibody titers in vaccinated mouse
sera, reactive with PR8 inﬂuenza virus, were detected using a
microneutralization assay, as described previously.20
2.7. Passive serum protection
Twenty-four BALB/c mice were divided into three groups: (1)
negative control mice were injected with serum from mice
previously treated with PBS; (2) mice were injected with serum
from mice vaccinated three times with FluMist; and (3) mice were
injected with serum from mice vaccinated with PR8 inﬂuenza
virus. Serum samples were pooled and incubated at 56 8C for
30 min before injection. Two hundred microliters of inactivated
mouse serum was injected into the tail vein on days 0, 1, and
3 post-challenge. Mice were challenged with 100  LD50 PR8
inﬂuenza virus and monitored daily after challenge.
2.8. Depletion of CD4+ and CD8+ T-cells in vivo
To test the role of T-cells in the cross-protection induced by
FluMist vaccine, mice were vaccinated with FluMist on days 0, 14,
and 28. Mice were challenged with 100  LD50 PR8 inﬂuenza virus
on day 42 post-vaccination. On days 1 and 3 before challenge, and
day 1 after challenge, groups of mice were injected intraperitoneally
with rat anti-mouse antibodies: 100 mg anti-CD4+ antibody, 100 mg
anti-CD8a+, 100 mg CD4+ and 100 mg CD8+ antibodies, or 100 mg rat
IgG2a isotype control (BD Pharmingen). After viral challenge, mice
were monitored daily for clinical symptoms and survival.
2.9. Virus isolation in mice challenged with FM/47 (H1N1) and HK/68
(H3N2)
Mice were vaccinated with FluMist three times. At 14 days after
the last vaccination, mice were challenged with 105 PFU FM/47
(H1N1) or HK/68 (H3N2) inﬂuenza virus. At 4 days post-challenge,
mice were euthanized. Each lung was collected and homogenized
in 0.5 ml PBS. After centrifugation, the viral burden in supernatants
was measured by plaque assay on MDCK cell monolayers.
2.10. Statistical analysis
Statistical analyses were performed using GraphPad Prism
5. The data were expressed as the mean  standard deviation.
Analysis of variance (ANOVA) and/or the Student’s t-test were used
for comparisons. A p-value of less than 0.05 was considered
statistically signiﬁcant.Figure 1. Intranasal vaccination with FluMist induced heterologous protection. Groups of
55 ml FluZone, and then boosted at day 28 post-vaccination with the same dose of FluMist
manufacturer’s indication, intranasally and intramuscularly, respectively. In one group (
10 ml FluMist in 40 ml PBS; in another group, mice (marked with ‘i.n.’) were primed and
inoculated intranasally with 50 ml PBS. At 42 days post-vaccination, mice were lethally ch
weights of mice in the FluMist + FluMist group decreased less than weights in other grou
each group.).3. Results
3.1. Seasonal LAIV (FluMist) vaccination induces protection against
lethal challenge with inﬂuenza H1N1 PR8 virus
The 2011–2012 seasonal FluMist and FluZone vaccines are
designed to protect against three viral strains: A/California/7/2009
(H1N1), A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008. To
determine whether vaccination with FluZone and FluMist could
induce broad protection against heterologous inﬂuenza infection,
BALB/c mice were initially vaccinated with FluZone or FluMist and
given boosts of FluMist or FluZone 28 days later. The results
showed that primary vaccination with FluMist induced some
protection against lethal PR8 inﬂuenza virus challenge and a boost
of FluMist increased protection (Figure 1). Animals primed and
boosted with FluMist were protected at a survival rate of 75%;
those primed with FluMist and boosted with FluZone were
protected at 50%; the group primed with FluZone and boosted
with FluMist was protected at 25% (Figure 1B). In contrast, the
group vaccinated with only FluZone had a survival rate of 12.5%.
After challenge, the weights of mice in the 2  FluMist group
decreased less than weights in the other groups (p < 0.001).
Next, speciﬁc antibody concentrations were determined for
each group and the results showed that primary vaccination with
either FluMist or FluZone induced high systemic levels of IgG when
boosted with FluMist, but intranasal vaccinations with FluZone
and intramuscular vaccinations with FluMist failed to induce a
strong humoral immune response (Figure 2A). Furthermore, prime
and boost with FluMist also induced high levels of mucosal IgA
(Figure 2B). We also measured the levels of IFN-g, TNF-a, IL-2, and
IL-4 cytokines in mouse lung alveolar ﬂuid. Prime and boost with
FluMist induced signiﬁcant levels of IL-2 and IFN-g (Figure 3A
and3B), while induction of TNF-a and IL-4 in lung alveolar ﬂuid
were low (data not shown).
3.2. Boost with FluMist enhances cross-strain protective immunity
As indicated in Figure 1, prime–boost with FluMist provided
better cross-protection against PR8 inﬂuenza virus than other
experimental groups. To determine if protection by FluMist is
dose-dependent, mice were vaccinated one to three times with
FluMist, then challenged with lethal PR8 inﬂuenza virus. As shown
in Figure 4, primary vaccination with FluMist followed by two
boosts improved cross-protection to 100% against heterologous
fatal PR8 inﬂuenza virus challenge in mice, while one vaccination
yielded a 37.5% survival rate. Furthermore, these mice recovered
their weight by 16 days post-challenge. These results suggest that
multiple vaccinations with FluMist could provide complete mice were vaccinated with 10 ml FluMist in 40 ml PBS (in a total volume of 50 ml) or
 or FluZone. Unless otherwise noted, FluMist and FluZone were administered are per
marked with ‘i.m.’), mice were primed and boosted via intramuscular injections of
 boosted with 55 ml FluZone intranasally. Mice in the negative control group were
allenged with 100  LD50 PR8 (H1N1) inﬂuenza virus. (A) Mouse weight change; the
ps (p < 0.001). (B) Mouse survival rates by different vaccination regimens. (n = 8 in
Figure 2. Measurement of anti-inﬂuenza IgG in sera and IgA in lung alveolar ﬂuid by
ELISA. (A) Mice were primed with 10 ml FluMist in 40 ml PBS or 55 ml FluZone, and
then boosted on day 28 with FluZone or FluMist, as indicated. Mouse blood was
collected and the anti-inﬂuenza IgG concentration in sera was measured
(*p < 0.01 compared with the negative PBS control group). (B) Mice were
administered with PBS, PR8, or FluMist intranasally, and lung alveolar ﬂuid was
collected on day 14 post-boost. Anti-inﬂuenza IgA in lung alveolar ﬂuid was
measured (****p < 0.0001 compared with the negative PBS control and PR8 groups).
(n = 8 in each group.).
Table 1
Microneutralization (MN) titers against PR8 (H1N1) inﬂuenza
virus in sera from vaccinated micea
Vaccination regimen MN titer in mouse sera
Control (PBS) <8
FluMist + FluMist <8
FluZone + FluZone (i.n.) <8
FluMist + FluZone <8
FluZone + FluMist <8
PR8 + PR8 >256
FluMist + FluMist (i.m.) <8
FluZone + FluZone <8
PBS, phosphate-buffered saline.
a Sera were collected from negative control (PBS) mice, or
mice vaccinated with FluMist or FluZone and boosted with
FluZone or FluMist, or positive control mice vaccinated
intranasally with PR8 inﬂuenza viruses. There are two special
groups: in one group (marked with ‘i.m.’), mice were injected
with 10 ml FluMist in 40 ml PBS and boosted with 10 ml FluMist
in 40 ml PBS; in another group, mice (marked with ‘i.n.’) were
primed and boosted intranasally with 55 ml FluZone.
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mice.
3.3. Vaccination with FluMist does not induce cross-reactive
neutralizing antibody
To analyze whether the humoral immune response contributes
to the cross-protection against heterologous lethal PR8 inﬂuenza
virus infection, antibody microneutralization assays were per-
formed using MDCK cells. The results demonstrated that vaccina-
tion with FluMist did not elicit high neutralizing serum antibody
titers against PR8 inﬂuenza virus (Table 1). To conﬁrm these results
in vivo, passive transfer of serum from vaccinated mice to naı¨ve
mice was performed and protection in these mice was evaluated
against challenge with PR8 virus. Passive injection of mice with
serum containing antibodies induced by FluMist did not provideFigure 3. Cytokine levels in lung alveolar ﬂuid of vaccinated mice as determined by ELISA
a 50-ml volume per animal, and then lung alveolar ﬂuid was collected at day 5 post-boos
(IFN-g) level in lung alveolar ﬂuid. (****p < 0.0001 compared with the negative PBS coprotection against infection by heterologous PR8 inﬂuenza virus
(Figure 5). Taken together, these results indicate that vaccination
with FluMist or FluZone does not produce neutralizing antibodies
against heterologous lethal inﬂuenza virus challenge in mice.
3.4. T-cells are crucial in the cross-protection induced by FluMist
vaccination
To further explore the mechanism of cross-protection against
heterologous lethal inﬂuenza viruses induced by vaccination with
FluMist, T-cell depletion studies were performed in vivo. Success-
ful depletion was conﬁrmed by ﬂow cytometry analysis of
peripheral blood mononuclear cells (PBMC) where 98% of CD4
and 96% of CD8 T-cells were depleted (data not shown). T-cell-
depleted mice were challenged with 100  LD50 PR8 inﬂuenza
virus. As shown in Figure 6, CD4+ T-cell-depleted mice had a 50%
survival rate and CD8+ T-cell-depleted mice had a 25% survival
rate. Mice injected with an isotype control all survived challenge.
Mice in the isotype control group recovered most of their initial
weights by day 16 post-challenge. These results suggest that CD8+
or CD4+ T-cell depletion impairs the cross-protection induced by
vaccination with FluMist.
3.5. FluMist vaccination induces protection against challenge with
heterologous inﬂuenza viruses FM/47 (H1N1) and HK/68 (H3N2)
To further conﬁrm that vaccination with FluMist can provide
heterologous protection against various inﬂuenza viruses, we
vaccinated mice with FluMist three times and challenged with FM/
47(H1N1) or HK/68(H3N2) inﬂuenza virus at 14 days after the last. Mice were primed on day 0, and then boosted on day 28 with PBS, PR8, or FluMist in
t. (A) Interleukin 2 (IL-2) concentration in lung alveolar ﬂuid. (B) Interferon gamma
ntrol group; n = 8 in each group.).
Figure 4. Protection conferred by FluMist is dose-dependent. Thirty-two BALB/c mice were divided into four groups randomly. The ﬁrst group was set as a negative control
group and was inoculated intranasally with 50 ml PBS one time at day 0. The second group was vaccinated intranasally with three doses of 10 ml FluMist in 40 ml PBS (total
volume of 50 ml per mouse) on day 0, day 15, and day 29. The third group was vaccinated with two doses of FluMist on day 15 and day 29. The fourth group was treated with
one dose of FluMist on day 29. All mice were challenged intranasally with 100  LD50 PR8 inﬂuenza virus on day 42. (A) Weight change caused by PR8 inﬂuenza virus
challenge. (B) Mouse survival rate following the challenge with PR8 inﬂuenza virus. (n = 8 in each group.).
Figure 5. Passive protection provided by injection with sera from mice vaccinated with PR8 inﬂuenza virus or FluMist. Mice were injected intraperitoneally with 200 ml sera
from negative control, PR8 vaccinated, or FluMist (three doses) vaccinated mice, and were then challenged with 100  LD50 PR8 inﬂuenza virus in 50 ml PBS. (A) Weight
change after mice were challenged with PR8 inﬂuenza virus. (B) Mouse survival rate after mice were challenged with PR8 inﬂuenza virus. (n = 8 in each group.).
Figure 6. Contribution of T-cells in protective immunity determined by T-cell depletion experiments in vivo. Cross-strain protective immunity induced by prime–boost
vaccination with FluMist was evaluated in mice depleted of T-cells (depletion of CD4+, CD8+, or both CD4+ and CD8+ T-cells). (A) Weight change in mice depleted of T-cells
after PR8 inﬂuenza virus challenge. (B) Mouse survival rates after PR8 inﬂuenza virus challenge. (n = 8 in each group.).
Figure 7. Intranasal vaccination with FluMist induced cross-strain protection. Mice in the negative control group were treated with 50 ml PBS. Mice in the positive control
groups were vaccinated with 10 PFU FM/47 (H1N1) or HK/68 (H3N2) inﬂuenza viruses in 50 ml PBS on day 0. FluMist groups were vaccinated with three doses of 10 ml FluMist
in 40 ml PBS on days 0, 15, and 29. On day 42, mice were challenged with 105 PFU FM/47 or HK/68 inﬂuenza virus in 50 ml PBS. (A) Viral titers in lungs of mice challenged with
FM/47 at 4 days post-challenge. (B) Viral titers in lungs of mice challenged with HK/68 at 4 days post-challenge. (***p < 0.001 compared with the negative control group;
n = 8 in each group.).
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lungs were collected for harvest of lung alveolar ﬂuid. The viruses
in lung alveolar ﬂuid were tested by plaque assay on monolayer
MDCK cells. FluMist also provided protection against FM/47 and
HK/68 inﬂuenza viruses, as shown in Figure 7.
4. Discussion
Current vaccine strategies against inﬂuenza focus on generating
robust antibody responses. Since the outbreak of 2009 pandemic
inﬂuenza, considerable interest has been revived on the development
of broadly protective inﬂuenza vaccines that would ideally afford
broad protection against various subtypes of inﬂuenza A virus. The
traditional strategies for creating a universal inﬂuenza vaccine focus
on the conserved epitopes of inﬂuenza protein, in particular the HA2
and M2 protein regions.21–24 However, several studies showed that
infection with seasonal inﬂuenza virus can provide cross-protection
against 2009 pandemic inﬂuenza virus, H5N1 inﬂuenza virus, and
even against the 1918 pandemic inﬂuenza virus.25–27 Moreover,
some results showed that infection with 2009 pandemic inﬂuenza
virus or vaccination with seasonal TIV could induce cross-reactive
immunity against 1918 H1N1 inﬂuenza virus.28–30 Furthermore,
previous infections with inﬂuenza virus may serve to prime future
inﬂuenza virus vaccinations.15,16 These studies indicate that there are
antigenic similarities among these viruses.
In this study, we tested whether multiple-dose combinations of
seasonal inﬂuenza vaccines FluZone or FluMist could provide
cross-protection against heterologous inﬂuenza virus infection.
Here, we used PR8 inﬂuenza virus as a heterologous inﬂuenza virus
model. In initial experiments, the survival rate of mice primed and
boosted with FluZone was only 12.5%. This result is in accordance
with the result observed by Manicassamy et al. in a mouse model
vaccinated intramuscularly with seasonal TIV and challenged with
2009 pandemic inﬂuenza virus.25 The survival rate of mice primed
and boosted with FluMist was 75% (p < 0.001) and the survival rate
of mice primed with FluMist and boosted with FluZone reached
50%. These results indicate that vaccination with FluMist provided
cross-protection against lethal PR8 challenge to some extent, while
vaccination with FluZone did not, although vaccination with
seasonal FluZone induced a strong humoral immune response. Of
note, the antibodies produced following varying prime–boost
regimens with FluZone and FluMist vaccines did not neutralize PR8
virus as tested in the microneutralization assays.
Apart from the humoral immune response, some studies have
indicated that there are other mechanisms capable of conferring
complete protection against heterologous inﬂuenza virus chal-
lenge. Studies have shown that seasonal inﬂuenza infection can
induce B-cell-dependent cross-protection or cross-reactive cyto-
toxic T-lymphocytes against 2009 pandemic H1N1 inﬂuenza virus,
and that seasonal FluMist vaccination also induces cross-reactive
T-cell immunity against 2009 H1N1 inﬂuenza virus.16,31–33 Results
published by Bodewes et al. suggested that vaccination with
seasonal inﬂuenza H3N2 virus induces T-cell-dependent hetero-
subtypic immunity against inﬂuenza H5N1 or 2009 pandemic
inﬂuenza virus infection in ferrets.34,35 Infection with pre-1950
H1N1 inﬂuenza viruses can also produce T-cell-mediated cross-
protection against the pandemic 2009 inﬂuenza viruses.36,37
Having observed such promising results using a prime–boost
regimen with FluMist to protect against heterologous virus
challenge independent of neutralizing antibody, we decided to
vaccinate mice three times with FluMist and also evaluate T-cell
responses in addition to protection. The survival of mice vaccinated
three times with FluMist improved to 100% after challenge with PR8
virus. Although there was a substantial weight decrease in these
infected mice, they recovered completely by day 16 post-challenge.
Protection against two other heterologous viruses was alsoobserved. Of signiﬁcance, this cross-strain protective immunity
was found to be T-cell-dependent, as depletion of CD4+, CD8+, or
both T-cell types greatly diminished protection. Furthermore,
signiﬁcant secretion of IFN-g and IL-2 cytokines into the lung
alveolar ﬂuid of mice primed and boosted with FluMist corroborated
a role for T-cells in cross-protective immunity.
Several other studies have observed that inﬂuenza-speciﬁc CD8
T-cells are stimulated in the lung of mice infected with seasonal
attenuated or wild-type inﬂuenza virus. Furthermore, CD8 T-cells
contribute to viral clearance in the lungs via lysis of target cells
following exocytosis of granules containing perforin and gran-
zymes.38,39 On the other hand, cross-reactive CD4 T-cells are
primarily responsible for helping other immune cells through
direct cell-to-cell interactions and by secreting cytokines, but are
also essential for establishing long-lasting CD8 T-cell memory,
antibody, and in vivo lytic activity, and contribute to viral
clearance.40,41 To date, little is known about the role of CD4
T-cells as direct mediators of effector function, but in mouse
models, several inﬂuenza-speciﬁc CD4 epitopes have been
identiﬁed.42–46 Some studies have shown that NP- or M2-speciﬁc
CD4 epitopes are crucial for the cross-protection to heterologous
inﬂuenza virus infection.31,33,46,47 Other studies using animal
models have suggested that CD8 T-cells are more important than
CD4 T-cells for cross-protection.29,31,37,48,49 Fang et al. reported
that seasonal inﬂuenza virus infection also conferred cross-
reactive protection against 2009 pandemic H1N1 inﬂuenza virus
through a B-cell-dependent and CD8 T-cell-independent mecha-
nism.32 Our study showed both CD4+ and CD8+ to be important to
heterologous immunity, although depletion of CD8+ was more
detrimental to survival of mice primed and boosted with FluMist
than those depleted of CD4+ (25% to 50% survival, respectively).
Furthermore, vaccinated mice depleted of CD4+ and CD8+ T-cells
succumbed to lethal viral challenge and did not live signiﬁcantly
longer than the unvaccinated group of mice.
It was surprising that a multiple-dose LAIV vaccination regimen
was more protective than multiple doses of TIV, and induced T-cell
responses. As tested in young children, two doses of seasonal LAIV
is more protective against seasonal inﬂuenza than two doses of
seasonal TIV, and two-dose combinations with LAIV induce
inﬂuenza-speciﬁc CD4+, CD8+, and gd T-cells.50
In conclusion, our study is noteworthy in showing that multiple
doses of LAIV can provide T-cell-dependent protection against
various non-vaccine strains. Moreover, as multiple doses of LAIV
are approved for use in young children, it is presumed to be a safe
regimen. Thus, it is possible that prime–boost vaccination with
LAIV can be used in combating a potentially new inﬂuenza
epidemic, or an even more dangerous pandemic.
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